MIRA Pharmaceuticals, Inc.
MIRA
$1.42
-$0.01-0.70%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 1.05M | 1.49M | 1.58M | 1.01M | 1.12M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.55M | 1.81M | 2.44M | 2.08M | 1.73M |
| Operating Income | -1.55M | -1.81M | -2.44M | -2.08M | -1.73M |
| Income Before Tax | -1.54M | -1.78M | -2.40M | -2.04M | -1.69M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -1.54M | -1.78M | -2.40M | -2.04M | -1.69M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1.54M | -1.78M | -2.40M | -2.04M | -1.69M |
| EBIT | -1.55M | -1.81M | -2.44M | -2.08M | -1.73M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -0.09 | -0.11 | -0.14 | -0.14 | -0.11 |
| Normalized Basic EPS | -0.06 | -0.07 | -0.09 | -0.08 | -0.07 |
| EPS Diluted | -0.09 | -0.11 | -0.14 | -0.14 | -0.11 |
| Normalized Diluted EPS | -0.06 | -0.07 | -0.09 | -0.08 | -0.07 |
| Average Basic Shares Outstanding | 16.99M | 16.65M | 16.56M | 15.07M | 14.78M |
| Average Diluted Shares Outstanding | 16.99M | 16.65M | 16.56M | 15.07M | 14.78M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |